Maria Lund

Maria’s career in biotech has focused on the translation of breakthrough, early stage technologies, in diseases of huge clinical unmet need. In her role at IP Group Australia, Maria is responsible for evaluating and progressing exciting new technologies with our university partners, across Australia and New Zealand. Maria brings a wealth of experience across the drug development path, from bench to the clinic.

Maria has held positions in preclinical and clinical stage start-up companies, in the therapeutic areas of oncology and autoimmune disease, supporting the development of new drugs from the research setting through to clinical trials. Her doctoral work led to a start-up company to progress novel peptide therapeutics for autoimmune disease, and, most recently, Maria led the preclinical program at an immuno-oncology start-up, developing antibody therapeutics for solid tumours. Maria holds a PhD in the field of Immunology from the University of Technology Sydney and a Bachelor (Hons) in Medical Science.